Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 386

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 386
---
: we have accumulated over 114 terabytes of genomic data specific to the Latin American population, one of the most underrepresented groups in global databases. This unique data enables us to deliver more accurate and region -specificinsights. In addition, our tests are designed to provide actionable results that combine genetic, microbiome, epigenetic, and lifestyle data, supporting a more comprehensive, data -drivenapproach to health and wellness. • Localized, Efficient and Accessible Solutions: we prioritize low -cost, high -qualitysolutions, with optimized turnaround times that will be made possible by our wet -labsand streamlined logistics network. This approach enables us to deliver results efficiently and make our services accessible to a wider audience, distinguishing us in a market often dominated by more costly and less regionally adapted services. For example, our products and services will be built on localized genomic datasets, while our results and client services will be provided in Spanish, meeting the specific cultural needs of each market. 192 • Data -Driven Approach and AI Integration: we are building a proprietary, omni -modaldata lake that integrates genomic, microbiome, and lifestyle data. This robust data foundation will fuel our AI capabilities, allowing us to offer precision -basedhealth management and prevention tools specifically tailored to the Latin American population. As AI and next -generationDNA sequencing costs decrease, we are well -positionedto optimize prevention and health management solutions with increasingly sophisticated and cost -effectivetechnologies. • Telemedicine and Localized Support: through our services, we will offer telemedicine consultations that integrate AI Agents with access to specialists and medical geneticists when human expertise is required. These consultations will provide personalized health guidance based on genetic and microbiome insights, ensuring in -depthknowledge and recommendations of local diets and health habits. Our hybrid telemedicine model will support local health management by connecting customers with qualified experts, reinforcing our commitment to proactive health management in Latin America. We believe that these strengths allow us to compete favorably with other players in our sector. Although many competitors have a longer operating history, larger customer bases, greater brand recognition, or more resources, our unique market positioning, data -drivenapproach, and local partnerships enable us to address the specific needs of the Latin American market effectively. Seasonality Our business remains largely unaffected by seasonal patterns and external factors that influence other industries. However, as we enter new markets and launch new products, seasonality may become more pronounced, potentially causing fluctuations in our operating results. Regulation We are, and will